Yi-Long Wu and Caicun Zhou on non-small-cell lung cancer

The Lancet Oncology in conversation with - A podcast by The Lancet Group

Categories:

Education

Prof Yi-Long Wu (Guangdong Lung Cancer Institute, Guangzhou, China) and Prof Caicun Zhou (Shanghai Pulmonary Hospital, Shanghai, China) discuss the GEMSTONE 301 and GEMSTONE 302 trials on sugemalimab versus placebo in non-small-cell lung cancer. Read the full articles: Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301) Sugemalimab versus placebo, in combinat...